EP2984170A4 - Use of antibody-urease conjugates for diagnostic and therapeutic purposes - Google Patents

Use of antibody-urease conjugates for diagnostic and therapeutic purposes

Info

Publication number
EP2984170A4
EP2984170A4 EP14782795.0A EP14782795A EP2984170A4 EP 2984170 A4 EP2984170 A4 EP 2984170A4 EP 14782795 A EP14782795 A EP 14782795A EP 2984170 A4 EP2984170 A4 EP 2984170A4
Authority
EP
European Patent Office
Prior art keywords
diagnostic
antibody
therapeutic purposes
urease conjugates
urease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP14782795.0A
Other languages
German (de)
French (fr)
Other versions
EP2984170A1 (en
Inventor
Heman Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helix Biopharma Corp
Original Assignee
Helix Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biopharma Corp filed Critical Helix Biopharma Corp
Publication of EP2984170A1 publication Critical patent/EP2984170A1/en
Publication of EP2984170A4 publication Critical patent/EP2984170A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01005—Urease (3.5.1.5)
EP14782795.0A 2013-04-08 2014-04-03 Use of antibody-urease conjugates for diagnostic and therapeutic purposes Pending EP2984170A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361809842P 2013-04-08 2013-04-08
PCT/CA2014/050334 WO2014165985A1 (en) 2013-04-08 2014-04-03 Use of antibody-urease conjugates for diagnostic and therapeutic purposes

Publications (2)

Publication Number Publication Date
EP2984170A1 EP2984170A1 (en) 2016-02-17
EP2984170A4 true EP2984170A4 (en) 2016-11-30

Family

ID=51688787

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14782795.0A Pending EP2984170A4 (en) 2013-04-08 2014-04-03 Use of antibody-urease conjugates for diagnostic and therapeutic purposes

Country Status (8)

Country Link
US (1) US10316311B2 (en)
EP (1) EP2984170A4 (en)
JP (1) JP2016524459A (en)
CN (2) CN105247047A (en)
AU (1) AU2014252666B2 (en)
CA (1) CA2908475C (en)
HK (1) HK1216903A1 (en)
WO (1) WO2014165985A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3261678B8 (en) * 2015-01-23 2021-03-17 Helix Biopharma Corp. Antibody-urease conjugates for therapeutic purposes
EP3515473A4 (en) 2016-09-24 2020-04-15 Helix Biopharma Corp. Restoring function of tumour acidified t cells
CN110382551A (en) * 2017-01-05 2019-10-25 赫利克斯生物药品公司 Anti-VEGFR-2 urase conjugate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US7211250B2 (en) * 2002-07-18 2007-05-01 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
WO2013185215A1 (en) * 2012-06-12 2013-12-19 Amorfix Life Sciences Ltd. Antibodies and conjugates that target misfolded prion protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218539A (en) * 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
US4360592A (en) * 1979-11-13 1982-11-23 Weltman Joel K Process for the detection of antibodies
US4657853A (en) * 1984-09-14 1987-04-14 E. I. Du Pont De Nemours And Company Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
US7723099B2 (en) * 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US7211250B2 (en) * 2002-07-18 2007-05-01 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
WO2013185215A1 (en) * 2012-06-12 2013-12-19 Amorfix Life Sciences Ltd. Antibodies and conjugates that target misfolded prion protein

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "ANTI-MOUSE IgG (WHOLE MOLECUKE) UREASE CONJUGATE - Product No. U1004", XP002763195, Retrieved from the Internet <URL:http://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Datasheet/8/u1004dat.pdf> [retrieved on 20161020] *
BAOMIN TIAN ET AL: "Production and Characterization of a Camelid Single Domain Antibody-Urease Enzyme Conjugate for the Treatment of Cancer", BIOCONJUGATE CHEMISTRY., vol. 26, no. 6, 17 June 2015 (2015-06-17), US, pages 1144 - 1155, XP055271801, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00237 *
CHAO H: "DOS47 - Killing cancer by altering the tumor microenvironment", DRUG DELIVERY TECHNOLOGY 2011 DRUG DELIVERY TECHNOLOGY USA, vol. 11, no. 1, January 2011 (2011-01-01), pages 68 - 72, XP002763192, ISSN: 1537-2898 *
HEMAN CHAO ET AL: "Development of an alkalizing antibody-enzyme conjugate for NSCLC treatment that is in Phase I clinical testing Preclinical Studies Abstract Background Starting Dose Derivations Acknowledgement", L-DOS47 PRESENTATION AT AACR 2013 ANNUAL MEETING, 5 April 2013 (2013-04-05), XP055285609, Retrieved from the Internet <URL:http://www.helixbiopharma.com/wp-content/uploads/2014/02/Helix-BioPharma-AACR.pdf> [retrieved on 20160704] *
KUMAR RAMESH K.: "Preparation of anti-human IgG-hrp conjugate and its use in ELISA and western blotting experiments", J. ANAL. BIOANAL. TECHNIQUES, vol. 3, no. 7, 2012, pages 85, XP002763194, ISSN: 2155-9872, DOI: 10.4172/2155-9872.S1.010 *
See also references of WO2014165985A1 *
WINSTON S E ET AL: "Chapter 11 - UNIT 11.1: Conjugation of Enzymes to AntibodiesConjugation of enzymes to antibodies.", CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (FREDERICK M. AUSUBEL ET AL), no. Supplement 50, 1 May 2001 (2001-05-01), pages 11.1.1 - 11.1.7, XP002763193, ISSN: 1934-3647, DOI: 10.1002/0471142727.mb1101s50 *

Also Published As

Publication number Publication date
AU2014252666A1 (en) 2015-11-12
WO2014165985A1 (en) 2014-10-16
US20160138002A1 (en) 2016-05-19
CA2908475A1 (en) 2014-10-16
CN109248311A (en) 2019-01-22
HK1216903A1 (en) 2016-12-09
CN105247047A (en) 2016-01-13
JP2016524459A (en) 2016-08-18
AU2014252666B2 (en) 2017-02-02
EP2984170A1 (en) 2016-02-17
US10316311B2 (en) 2019-06-11
CA2908475C (en) 2020-09-08

Similar Documents

Publication Publication Date Title
GB201302447D0 (en) Therapeutic and diagnostic target
HK1216903A1 (en) Use of antibody urease conjugates for diagnostic and therapeutic purposes
GB201303308D0 (en) Therapeutic and diagnostic target
GB201309498D0 (en) Novel diagnosis and therapy
GB201323065D0 (en) Therapeutic and diagnostic target
GB201323066D0 (en) Therapeutic and diagnostic target
GB201321846D0 (en) Therapeutic and diagnostic target
GB201319053D0 (en) Therapeutic and diagnostic target
GB201317849D0 (en) Therapeutic and diagnostic target
GB201316908D0 (en) Therapeutic and diagnostic target
GB201314515D0 (en) Therapeutic and diagnostic target
GB201314502D0 (en) Therapeutic and diagnostic target
GB201313865D0 (en) Therapeutic and diagnostic target
GB201311899D0 (en) Therapeutic and diagnostic target
GB201308759D0 (en) Therapeutic and diagnostic target
GB201308013D0 (en) Therapeutic and diagnostic target
GB201304740D0 (en) Therapeutic and diagnostic target
GB201304406D0 (en) Therapeutic and diagnostic target
GB201304402D0 (en) Therapeutic and diagnostic target
GB201303648D0 (en) Therapeutic and diagnostic target
GB201303573D0 (en) Therapeutic and diagnostic target
GB201303571D0 (en) Therapeutic and diagnostic target
GB201303535D0 (en) Therapeutic and diagnostic target
GB201303532D0 (en) Therapeutic and diagnostic target
GB201303529D0 (en) Therapeutic and diagnostic target

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161103

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20161026BHEP

Ipc: C07K 16/28 20060101ALN20161026BHEP

Ipc: C07K 16/00 20060101ALN20161026BHEP

Ipc: A61K 47/48 20060101AFI20161026BHEP

Ipc: C12N 9/96 20060101ALN20161026BHEP

Ipc: C12N 9/80 20060101ALN20161026BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180710

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS